News and Events
Revised ICHQ5A(R2) is adopted: call for action in viral safety testing!
The updated ICHQ5A(R2) guideline adopted in November 2023 highlights the benefits of Next Generation Sequencing assays versus in vivo assays: 3.2.3: "NGS is encouraged as a replacement for in vivo assays because it can overcome the limitations of the breadth and...
Webinar Replay – Integration Site Analysis: An innovative method for faster, more certain clone selection & genetic stability testing
Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to comprehensively sequence the junction site. This assay...
Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency.
Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French AgencyPathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...
PathoQuest Announces Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
PathoQuest Announces Publication of a Head-to-Head Study Validating Proprietary NGS Viral Safety Assay as a Reliable Alternative to Animal Testing NGS assay demonstrated a broader detection range than standard in vivo tests with comparable or higher analytical...
PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. site
PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. siteWe now offer our GMP validated Viral Vector Identity test at our Wayne, PA site, as well as at our site in Paris, France. Our NGS-based identity test is performed on a short read...
PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blog
PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blogA new post on Charles River’s Eureka science blog feature’s PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD,...
Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation Podcast
Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation PodcastDiscover how PathoQuest enables new biotherapies to be delivered rapidly and safely to patients with its quality testing platform in this episode of the AWS Health Innovation...
PathoQuest has partnered with Amazon Web Services
PathoQuest partners with Amazon Web Services to implement a GMP compliant, cloud-based computing and data storage platformPathoQuest has partnered with Amazon Web Services to implement a cloud-based computing and secure data storage platform that complies with Good...
Oxford Nanopore and PathoQuest announce next step of strategic collaboration
Oxford Nanopore and PathoQuest announce next step of strategic collaboration to bring to market the first sequencing-based quality control test for biopharma genetic characterisation Nanopore sequencing combined with PathoQuest expertise offers a new approach for...
PathoQuest Appoints Dr. Klaus Binder to Company’s Board of Directors
PathoQuest Appoints Dr. Klaus Binder to Company’s Board of DirectorsPathoQuest, the leading expert in GMP next-generation sequencing (NGS) services for biosafety testing, has announced that Klaus Binder, PhD has been appointed as a non-executive director to the...
Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral Vectors
Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral VectorsIdentity testing is critical for ensuring quality and safety of biopharmaceuticals. As such, identity testing is a key...
Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration
Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market Nanopore sequencing offers a transformational new approach for robust and accurate...
PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the Board
PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the BoardDaniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest. With over 25 years of hands-on...
PathoQuest Announce the Opening of its New U.S. Facility
PathoQuest Announce the Opening of its New U.S. Facility The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market Wayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader...
A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies
A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies Transgene is a French biotech developing virus-based immunotherapies. There manufacturing processes deal with breakthrough therapeutic vaccines highly awaited by...
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of DirectorsPARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment...
PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer
PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer PARIS, FRANCE, June 23, 2022 – PathoQuest, a leading Contract Research Organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies,...
PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer
PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer Dr. Sébastien Renouf has almost 20 years of experience in Regulatory Affairs, Risk Management, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining...
LOOK FOR US AT THESE UPCOMING MEETINGS
- BPI US West 2024 – March 11th-14th, San Diego, CA
- Swiss Biotech Days 2024 – April 22nd-24th, Basel, Switzerland

Contact us
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
E: contact@pathoquest.com
Sign up for our latest news
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
E: contact@pathoquest.com
How can PathoQuest help?
Sign up for our latest news